The first set of Phase 3 COVID-19 vaccine Is 90-per Cent Effective

The first interim analysis in Phase 3 Global study, according to BioNTech, shows that the vaccine could effectively prevent COVID-19.

According to BioNTech and Pfizer, the results of the first set of Phase 3 COVID-19 vaccine tests provide early evidence that the vaccine has the 90-per cent potential to cure the infection. 

KEY POINTS

• BioNTech and Pfizer say COVID-19 vaccine is 90-per cent effective.
• Meanwhile, the third phase of clinical trials of BNT162b2 began on July 27.
• Visit Lifestyle Uganda homepage for more stories like this.

Pfizer chairman Dr Albert Bourla said the results of the first set of Phase 3 COVID-19 vaccine trials provide early evidence that the vaccine has the potential to cure infections.

“Today is a great day for science and humanity. The results of the first set of our Phase 3 COVID-19 test provide early evidence of our vaccine’s ability to prevent COVID – 19, ”reads an excerpt from Dr Albert’s report.

He said with new records for epidemics, high-capacity hospitals and economies struggling to reopen, they are reaching an important milestone in developing the vaccine against the epidemic at a time when the world is most in need.

“With today’s news, we are an important step in delivering much needed improvements to people around the world to help put an end to this global health crisis. We look forward to sharing additional performance and safety data generated from thousands of participants. In the coming weeks.”

Meanwhile, the third phase of clinical trials of BNT162b2 began on July 27 and registered 43,538 participants, 38,955 of whom received the second dose of the vaccine candidate until November 8, 2020.

According to Professor Ugur Sahin, co-founder and CEO of BioNTech, the first interim analysis of the Global Phase 3 study provides evidence that the vaccine can effectively prevent COVID-19.

“The first interim analysis of our Global Phase 3 study provides evidence that a vaccine can effectively inhibit COVID-19. It is a breakthrough in innovation, science and global collaboration,” he said.

This comes at a time when the coronavirus continues to rise worldwide with confirmed cases hitting 50,891,706 by Monday afternoon. Of these, a total of 35,879,529 have recovered from the virus and 1,264,205 have been infected.

See the full statement from BioNTech and Pfizer here.